Saliva immunoassay for detection of antibodies for cardiovascular disease
View Patent ↗A method for diagnosing the likelihood and severity of cardiovascular disease in a patient is disclosed. The method determines the levels of antibodies against autoantigens, including myosin, oxidized LDL, β-2-glycoprotein, heat shock protein-60, platelet glycoprotein, and immune complexes. It then compares the results to normal levels to determine the likelihood and severity of cardiovascular disease.
1. A method for determining the likelihood of cardiovascular disease in a patient suspected of having cardiovascular disease, comprising the steps of:
a) determining a level of a panel of antibodies in a saliva sample from said patient, wherein each antibody in said panel binds to a different autoantigen contained in a group of autoantigens or a corresponding recombinant antigen or synthetic peptide thereof, wherein the group of autoantigens comprises myosin, oxidized LDL, heat shock protein-60, β-2-glycoprotein-1, and C1q immune complexes; and
b) comparing the level of antibodies determined in step a) with an average level of said antibodies in saliva from healthy control individuals, wherein
at least about three fold higher than control levels of all five of said autoantigen antibodies indicate the likelihood of cardiovascular disease.
2. The method according to claim 1 , wherein determining the level of antibodies in steps a) and b) is accomplished using an immunoassay.
3. The method according to claim 2 , wherein the immunoassay is an ELISA.
4. The method according to claim 1 , wherein the antibodies are IgA.